EyePoint Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Mar 8, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 8, 2024

EYPT$0.40+11.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(In thousands except share data)

Common Stock · Additional · AccumulatedOther · Total
	Number ofShares	Par ValueAmount	Paid-InCapital	AccumulatedDeficit	ComprehensiveIncome	Stockholders’Equity
Balance at January 1, 2022	33,905,826	$34	$752,602	$(569,097)	$841	$184,380
Net loss	—	—	—	(102,254)	—	(102,254)
Other comprehensive loss	—	—	—	—	(55)	(55)
Issuance of stock, net of issue costs	—	—	20	—	—	20
Employee stock purchase plan	47,787	—	354	—	—	354
Exercise of stock options	4,479	—	41	—	—	41
Vesting of stock units	124,842	—	(295)	—	—	(295)
Stock-based compensation	—	—	14,177	—	—	14,177
Balance at December 31, 2022	34,082,934	$34	$766,899	$(671,351)	$786	$96,368
Net loss	—	—	—	(70,795)	—	(70,795)
Other comprehensive gain	—	—	—	—	78	78
Issuance of stock, net of issue costs	14,432,180	15	225,392	—	—	225,407
Employee stock purchase plan	107,056	—	422	—	—	422
Exercise of stock options	260,321	—	2,955	—	—	2,955
Vesting of stock units	160,583	—	(169)	—	—	(169)
Stock-based compensation	—	—	12,057	—	—	12,057
Balance at December 31, 2023	49,043,074	$49	$1,007,556	$(742,146)	$864	$266,323

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.